Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergie neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Abstract: A cell population comprising Corin- and/or Lrtm1-positive cells was produced by the following steps (1) and (2), from which Corin positive and/or Lrtm1 positive cells are collected using a substance that binds to Corin and/or a substance that binds to Lrtm1, and dopaminergic neuron progenitor cells are produced by performing suspension culture of the Corin positive and/or Lrtm1 positive cells in a culture solution containing one or more nutritional factors: (1) a step of performing adhesion culture of pluripotent stem cells in a medium for maintaining undifferentiated state containing a Sonic hedgehog (SHH) signal stimulant, and an undifferentiated state-maintaining factor in the absence of feeder cells but in the presence of an extracellular matrix, and (2) a step of culturing the cell population obtained in the step (1) in a culture solution containing one or more differentiation-inducing factors.

Abstract: An object of the present invention is to provide a vehicle and a composition for transplantation comprising retinal tissue and the vehicle, which are for the treatment of retinal degenerative diseases such as retinitis pigmentosa (RP) and are suitable for the subretinal transplantation of retinal tissue. The vehicle for transplantation of the present invention is a vehicle for transplantation for subretinally transplanting retinal tissue, the vehicle having a viscosity of 5 to 500 mPa·s at a shear rate of 2 (1/s) at 25° C., and comprising hyaluronic acid and a pharmaceutically acceptable aqueous liquid. The composition for transplantation of the present invention comprises transplant retinal tissue and the vehicle for transplantation of the present invention.

Abstract: An object of the present invention is to provide a complex containing two or more neural retina-containing cell aggregates, and a method for manufacturing the same. The complex of the present invention is a complex comprising: two or more cell aggregates each containing a neural retina derived from a pluripotent stem cell; and a matrix, the two or more cell aggregates being arranged in the matrix. The method for manufacturing the complex of the present invention is a method for manufacturing a complex in which two or more neural retina-containing cell aggregates are arranged in a matrix, comprising: (1) a first step of preparing two or more cell aggregates of neural retinas from a pluripotent stem cell; and (2) a second step of contacting the two or more cell aggregates in a predetermined arrangement with the matrix or a precursor of the matrix, followed by the gelation of the matrix.

Abstract: A sphere-like cell aggregate according to one embodiment of the present invention comprises: a core part containing neural retina; and a covering part continuously or discontinuously covering at least a portion of a surface of the core part.

Abstract: The present invention aims to provide a method for preparing an RPE cell, and an RPE cell prepared by the method, and a reagent for producing an RPE cell which is suitable for the method. The method of the present invention includes the following step: a step of introducing, as exogeneous factors, MITF (Microphthalmia-Associated Transcription Factor) gene or an expression product thereof, OTX2 (Orthodenticle homeobox 2) gene or an expression product thereof, LIN28 gene or an expression product thereof, and L-MYC gene or an expression product thereof into a mammalian somatic cell.

Abstract: The present disclosure provides a method for producing a frozen body of a three-dimensional tissue aggregate of retinal pigment epithelial cells, the method including a step of preparing the three-dimensional tissue aggregate of the retinal pigment epithelial cells, and a step of subjecting the three-dimensional tissue aggregate of the retinal pigment epithelial cells to a freezing treatment at a predetermined freezing temperature set in advance using, as an index, the occurrence rate of a linear aggregate of dead cells in the three-dimensional tissue aggregate of the retinal pigment epithelial cells after thawing, thus obtaining the frozen body.

Abstract: The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell.

Abstract: Provided is a novel therapeutic agent for a disease caused by a dominant gene mutation (7). A therapeutic agent of the present invention comprises a donor DNA (20) that contains a polynucleotide having the following sequences (a) to (c): (a) a normal gene (1); (b) a first reverse target sequence (2a) that is located upstream of the normal gene (1) and that is cleaved by a designer nuclease; and (c) a second reverse target sequence (2b) that is located downstream of the normal gene (1) and that is cleaved by the designer nuclease, where the reverse target sequences (2a, 2b) each mean a sequence obtained by inverting a target sequence (6) that is present in the genome and that is cleaved by the designer nuclease.

Abstract: Provided is a composite comprising a neural retina, a retinal pigment epithelial cell sheet, and a hydrogel.

Abstract: The present invention provides a method for producing a retinal cell or a retinal tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension in a medium containing a Wnt signal transduction pathway inhibiting substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a Wnt signal transduction pathway inhibiting substance in a medium containing a BMP signal transduction pathway activating substance to obtain an aggregate containing a retinal cell or a retinal tissue.

Abstract: The method disclosed herein is for evaluating the quality of a transplant neural retina by sampling a part or the whole of a cell aggregate containing a neural retina having an epithelial structure derived from a pluripotent stem cell as a sample for quality evaluation.

Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.

Abstract: The present invention provides a method of producing a cell sheet comprising a retinal pigment epithelial cell layer and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells, comprising a step of laminating the retinal pigment epithelial cell layer and the vascular forming cell layer, and a cell sheet obtained by said method. Furthermore, the present invention provides a cell sheet for transplantation, comprising a cell layer formed with retinal pigment epithelial cells obtained by inducing differentiation of stem cells or progenitor cells ex vivo, a basement membrane secreted from said cells, and a vascular forming cell layer composed of stem cells having vascular formation ability or blood vessel constituting cells.

Abstract: The present invention aims to provide a method for suppressing differentiation of ganglion cell, amacrine cell, horizontal cell and/or bipolar cell in a neural retina tissue containing photoreceptor precursor and/or photoreceptor, and the like. A method for suppressing differentiation of a ganglion cell, an amacrine cell, a horizontal cell and/or a bipolar cell in a neural retinal tissue containing a photoreceptor precursor and/or a photoreceptor, including a step of culturing a retinal tissue comprising a neural retinal progenitor cell and in any stage between a differentiation stage immediately after emergence of a ganglion cell and a differentiation stage where emergence rate of a cone photoreceptor precursor reaches maximum in a medium containing a thyroid gland hormone signal transduction pathway agonist.

Abstract: The present invention aims to provide a retinal tissue rich in cone photoreceptor precursors and/or cone photoreceptors, a retinal tissue rich in rod photoreceptor precursors and/or rod photoreceptors, and a production method thereof and the like.

Abstract: An object of the present invention is to provide a method for preserving neural tissue for several hours to several weeks without freezing, a preservation solution therefor, a transport method for neural tissue in accordance with the method and using the preservation solution, and a composition for transplantation. The preservation method for neural tissue, comprising preserving neural tissue in a preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM at a preservation temperature of 8° C. to 30° C. The preservation solution having a potassium ion concentration of more than 0 mM and less than 115 mM, for preserving neural tissue derived from pluripotent stem cells at a preservation temperature of 8° C. to 30° C.